Isis 678354 Sodium Salt

6 trials 2 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

2 Recruiting

4 Completed trials

1 Sponsors

19 Countries

Phase III

Phase III: 6

Indications tested

Familial hypertriglyceridaemia 3

Sponsors using this IMP

Ionis Pharmaceuticals Inc. 6

All trials

6 total

A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Recruiting

2022-501999-26-00 Phase III 19 countries Ionis Pharmaceuticals Inc.
An Open-Label Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS) Previously Tre… Recruiting

2023-508815-22-00 Phase III 1 country Ionis Pharmaceuticals Inc.
An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered to Patients with Familial Chylomicronemia Syndrome (FCS) Ended

2023-509029-29-00 Phase III 7 countries Ionis Pharmaceuticals Inc.
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hype… Ended

2022-503022-13-00 Phase III 13 countries Ionis Pharmaceuticals Inc.
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended

2022-501420-20-00 Phase III 15 countries Ionis Pharmaceuticals Inc.
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia. Ended

2024-510696-38-00 Phase III 15 countries Ionis Pharmaceuticals Inc.

Showing 1–6 of 6 trials

← All drugs A–Z